A direct comparison of anti-microRNA oligonucleotide potency

Author(s): Lennox KA, Behlke MA

Abstract

Purpose Cataloguing endogenous miRNA targets by inhibiting miRNA function is fundamental to understanding the biological importance of each miRNA in gene regulatory pathways. Methods to down-regulate miRNA activity may help treat diseases where over-expression of miRNAs relates to the underlying pathophysiology. This study objectively evaluates the in vitro potency of different anti-miRNA oligonucleotides (AMOs) using various design and modification strategies described in the literature as well as some novel modification strategies. Methods MiR21 and miR16 AMOs, containing chemical modifications such as 2′-O-methyl RNA, locked nucleic acid and 2′-Fluoro bases with or without phosphorothioate linkages, were directly compared by transfection into HeLa cells using a dual-luciferase reporter assay to quantify miRNA inhibition. Results Potency for the various AMOs ranged from inactive at high dose (50 nM) to strongly inhibitory at both high and low dose (1 nM). Including phosphorothioate linkages improved nuclease stability and generally increased functional potency. Conclusions Incorporating high binding affinity modifications, such as LNA and 2′F bases, increases AMO potency while maintaining specificity; nevertheless, use of low dose is preferred when using high potency reagents to minimize the potential for cross reactivity. 2′OMe/LNA chimeras with PS modifications were the most potent constructs tested for miRNA inhibition in vitro.

Similar Articles

Role of Interferons in the Development of Diagnostics, Vaccines, and Therapy for Tuberculosis

Author(s): Chin KL, Anis FZ, Sarmiento ME, Norazmi MN, Acosta A, et al.

Role of Type I and II Interferons in Colorectal Cancer and Melanoma

Author(s): Di Franco S, Turdo A, Todaro M, Stassi G

Innate immune response induced by gene delivery vectors

Author(s): Sakurai H, Kawabata K, Sakurai F, Nakagawa S, Mizuguchi H, et al.

Analysis of Pro-inflammatory Cytokine and Type II Interferon Induction by Nanoparticles

Author(s): Potter TM, Neun BW, Rodriguez JC, Ilinskaya AN, Dobrovolskaia MA, et al.

More than 70 years of pyrogen detection: Current state and future perspectives

Author(s): Fennrich S, Hennig U, Toliashvili L, Schlensak C, Wendel HP, et al.

Evidence for the detection of non-endotoxin pyrogens by the whole blood monocyte activation test

Author(s): Hasiwa N, Daneshian M, Bruegger P, Fennrich S, Hochadel A, et al.

International validation of novel pyrogen tests based on human monocytoid cells

Author(s): Hoffmann S, Peterbauer A, Schindler S, Fennrich S, Poole S, et al.

Nucleic acids as therapeutic agents

Author(s): Alvarez-Salas LM

Immune stimulation--a class effect of phosphorothioate oligodeoxynucleotides in rodents

Author(s): Monteith DK, Henry SP, Howard RB, Flournoy S, Levin AA, et al.

Aptamers as therapeutics

Author(s): Keefe AD, Pai S, Ellington A

5'-triphosphate RNA requires base-paired structures to activate antiviral signaling via RIG-I

Author(s): Schmidt A, Schwerd T, Hamm W, Hellmuth JC, Cui S, et al.